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Mesenchymal stromal cells (MSCs) have potent immunomodulatory properties that
make them an attractive tool against graft- vs.-host disease (GVHD). However, despite
promising results in phase I/II studies, bone marrow (BM-) derived MSCs failed to
demonstrate their superiority over placebo in the sole phase III trial reported thus far.
MSCs from different tissue origins display different characteristics, but their therapeutic
benefits have never been directly compared in GVHD. Here, we compared the impact
of BM-, umbilical cord (UC-), and adipose-tissue (AT-) derived MSCs on T-cell function
in vitro and assessed their efficacy for the treatment of GVHD induced by injection
of human peripheral blood mononuclear cells in NOD-scid IL-2Rγnull HLA-A2/HHD
mice. In vitro, resting BM- and AT-MSCs were more potent than UC-MSCs to inhibit
lymphocyte proliferation, whereas UC- and AT-MSCs induced a higher regulatory T-cell
(CD4+CD25+FoxP3+)/T helper 17 ratio. Interestingly, AT-MSCs and UC-MSCs activated
the coagulation pathway at a higher level than BM-MSCs. In vivo, AT-MSC infusions were
complicated by sudden death in 4 of 16 animals, precluding an analysis of their efficacy.
Intravenous MSC infusions (UC- or BM- combined) failed to significantly increase overall
survival (OS) in an analysis combining data from 80 mice (hazard ratio [HR] = 0.59,
95% confidence interval [CI] 0.32–1.08, P = 0.087). In a sensitivity analysis we also
compared OS in control vs. each MSC group separately. The results for the BM-MSC
vs. control comparison was HR = 0.63 (95% CI 0.30–1.34, P = 0.24) while the figures
for the UC-MSC vs. control comparison was HR = 0.56 (95% CI 0.28–1.10, P = 0.09).
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Altogether, these results suggest that MSCs from various origins have different effects
on immune cells in vitro and in vivo. However, none significantly prevented death from
GVHD. Finally, our data suggest that the safety profile of AT-MSC and UC-MSC need to
be closely monitored given their pro-coagulant activities in vitro.
Keywords: mesenchymal stromal cells, graft-vs.-host-disease, hematopoietic stem cell transplantation,
xenogeneic, NSG, bone marrow, umbilical cord, adipose tissue
INTRODUCTION
Allogeneic hematopoietic cell transplantation (allo-HCT) has
remained the best therapeutic option for many patients
with hematological or immune disorders (1). Its efficacy
in hematological malignancies depends not only on the
chemo/radiotherapy given in the conditioning regimen, but
also on graft-vs.-tumor (GvT) effects mediated mainly through
donor T cells contained in the graft (2, 3). However, donor T
cells can also recognize the tissues of the recipient as foreign,
causing graft-vs.-host disease (GVHD) (4–6), a life-threatening
complication of allo-HCT (7, 8). The complex physiopathology
of acute GVHD involves both innate and adaptive immune
activation in response to inflammatory triggers such as damage-
associated molecular pattern (DAMP) molecules released from
damaged cells or extracellular matrix, and pathogen-associated
molecular pattern (PAMP) molecules from bacteria, viruses and
fungi. The main effectors of acute GVHD are donor CD4+
and CD8+ T cells, the latest causing tissue damages through
expression of FAS ligand and release of granzyme B, perforin and
cytokines such as tumor necrosis factor-alpha (TNFα). CD4+ T-
cell activation, differentiation, and survival require three signals:
(1) interaction of T-cell receptor (TCR) with antigen presenting
cells (APCs) expressing host major histocompatibility complex
(MHC) and/or host minor histocompatibility antigens, (2)
positive costimulatory signals (including CD28, ICOS, CD40L,
OX40, 4-1BB) and (3) cytokines such as interleukin (IL)-2,
IL-7, IL-15, and polarizing T helper 1 (Th1), Th2 and Th17
cytokines (9). Regulatory mechanisms include mainly regulatory
T cells (Tregs; CD4+CD25+FoxP3+), but also type 1 regulatory T
cells (Tr1) secreting IL-10, myeloid-derived suppressor cells and
tolerogenic dendritic cells (9).
GVHD has remained a serious limitation of allo-HCT (7, 8).
Only half of the patients respond to first-line steroid therapy,
and the outcome of patients with steroid-refractory GVHD has
remained dismal (10). Therefore, there is a real need for new
effective strategies to treat acute GVHD.
Mesenchymal stromal cells (MSCs) are multipotent
progenitors within the bone marrow capable of differentiating
into various cells and tissues, such as chondrocytes,
osteoblasts and adipocytes (11). In addition to their support
to hematopoiesis, MSCs have demonstrated potent tissue
repair abilities and immunomodulatory properties (12, 13).
Specifically, MSCs interact with lymphocytes, natural killer
(NK) cells and APCs, through release of soluble factors [such
as prostaglandin-E2, transforming growth factor beta-1, or
human leukocyte antigen [HLA]-G but also, as recently
reported, programmed death-ligand [PD-L] 1 and PD-L2 (14)],
induction of indoleamine 2,3 dioxygenase (IDO), and/or cell
contact signaling (12, 13). Importantly, MSCs have similar
immunosuppressive potency against autologous and allogeneic
lymphocytes. All these characteristics make them a promising
tool against GVHD (15–17).
In the last 2 decades, MSC infusions have been evaluated for
both prevention and treatment of GVHD. A number of phase II
trials reported lower incidences of acute GVHD in patients co-
transplanted with MSCs than in historical or concurrent controls
(18–20). However, a meta-analysis of trials of MSC infusion
in the setting of GVHD prophylaxis failed to demonstrate a
significant impact of MSC infusion on GVHD (21). Among the
phase I/II trials assessing the efficacy of allogeneic MSCs for the
treatment of steroid refractory acute GVHD, complete response
(CR) rates varied between 10 and 75% (22–24), providing a
median 6-month survival of 63% (95% CI 50–74%) after MSC
infusion in another large meta-analysis (25). Importantly, the
sole randomized placebo-controlled phase III trial assessingMSC
infusions as treatment for steroid-refractory GVHD reported
thus far failed to reach the primary endpoint (increase in the
rates of durable [≥28 days] CR) (26). The heterogeneity in the
design of these studies as well as the heterogeneity in MSC
products used might have participated in the discrepancies
between their results. Based on these observations, a recent
trial aimed at selecting subjects likely to be responders, in light
of the results of the first clinical studies. Early MSC therapy
in pediatric gut and/or liver steroid-refractory GVHD seems
indeed promising with improvement of overall response at day
28 (CR + partial response [PR]: 69%) (27), although the final
results of the trial have not been published yet. MSCs can also
display pro-inflammatory properties (including secretion of pro-
inflammatory cytokines such as IL-6 and IL-8) that may hamper
their efficacy (28). These findings stress the need for more pre-
clinical studies aiming to amore thorough understanding ofMSC
mechanisms of action and parameters of efficacy.
Since their first discovery in bone marrow (BM), MSCs
have been successfully isolated from several other tissues,
including adipose tissue (AT), umbilical cord (UC), umbilical
cord blood, and placenta. MSCs from different sources share
many characteristics, but also display many phenotypical and
functional differences (29, 30). Although they all exhibit
immunomodulatory properties, few studies directly compared
their therapeutic benefits. Here, we compared the ability of BM-
MSCs, AT-MSCs, and UC-MSCs to treat GVHD in NOD-scid
IL-2Rγnull HLA-A2/HHD (NSG-HLA-A2/HHD) mice infused
with human peripheral blood mononuclear cells (PBMCs) from
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non-HLA-A2 donors. We recently demonstrated that GVHD in
that humanized model is caused by a limited number of CD4 and
CD8 xeno- as well as probably allo- reactive T-cell clones that
expand via activation of the TCR, costimulation, IL-2/STAT5,
mTOR, and Aurora kinase A pathways and differentiate into
effector cells in GVHD-target organs, secreting high amounts of
interferon gamma (IFNγ) and TNFα (31). This model mimics




BM-MSCs were produced at the Laboratory of Cellular and
Genic Therapy (LTCG, CHU Liège, Belgium) under GMP
condition as previously described (33). UC-MSCs were isolated
in our Hematology Research Unit (GIGA-I3, University of Liège,
Belgium). Umbilical cords were provided by the maternity ward
of the Center Hospitalier du Bois de l’Abbaye (Liège, Belgium),
with informed consent of the mothers. Briefly, umbilical cord
segments of approximately 5 cm were cut longitudinally to
increase the contact area and plated onto a plastic surface for
5 days in Dulbecco’s Modified Eagles Medium–Low Glucose
with Glutamax (DMEM-GLX, Fisher-Bioblock, Invitrogen,
Merelbeke, Belgium) supplemented with 10% gamma-irradiated
Fetal Bovine Serum (FBS, Hyclone, Perbio Sciences, Utah, USA)
and antibiotics (Penicillin/Streptomycin [P/S]). After 5 days, the
cord segments were removed and the culture was pursued until
subconfluency. AT-MSCs were provided by the Endocrine Cell
Therapy unit of the Cliniques Universitaires Saint-Luc (Brussels,
Belgium), and produced as previously described (34).
All MSCs were cryopreserved at passage 2 or 3, then thawed
and cultured 1–2 week(s) before trypsinization and injection to
mice or use in in vitro experiments.
MSC / PBSC Co-Cultures
MSCs (1 × 104 or 2 × 104) were plated in flat-bottom
96-well plates (Becton–Dickinson) in RPMI 1,640 medium
supplemented with 10% FBS, penicillin (100 U/ml), streptomycin
(100 mg/ml), l-glutamine (2mM) (all from Lonza), sodium
pyruvate (100mM), non-essential amino acids (100mM), and
β-mercaptoethanol (5 × 10−5 M) (all from Gibco, Merelbeek,
Belgium). For inflammatory stimulation, MSCs were incubated
with IFNγ 10 ng/ml and TNFα 15 ng/ml during 40 h before
harvest. For PBMC proliferation assays, MSCs were irradiated at
22Gy using a 137Cs source (GammaCell 40, Nordion, Ontario,
Canada) after 4-h incubation to reduce their proliferation.
Allogeneic human PBMCs were isolated from blood samples
of healthy volunteer donors by Ficoll PaqueR Plus density
gradient. For lymphocyte proliferation assays, PBMCs were
stained with CFSE using a CellTrace CFSE Cell Proliferation
Kit (Thermofisher) according to the manufacturer’s instructions.
PBMCs (1 × 105) were added to wells in a total volume of 200
µl containing or not irradiated MSCs, in the presence of anti-
CD3/CD28microbeads (Invitrogen, Dynal A/S, Oslo, Norway) at
a bead/cell ratio of 1:1 in proliferation assays and 1:5 in the other
experiments. Recombinant human IL-2 300 U/ml (PeproTech,
USA) was added for the regulatory T-cell (Treg) assays. Cells were
incubated at 37◦C during 3–7 days depending on the assay, and
collected at different time points for FACS analysis.
Humanized Mouse Model of Graft-vs.-Host
Disease
All experimental procedures and protocols used in this
investigation were reviewed and approved by the Institutional
Animal Care and Use Committee of the University of
Liège, Belgium (Certification No. 1480). Animal welfare was
assessed at least once per day. We used NOD-scid IL-2Rγnull
(NSG) mice expressing the HHD construct designed for the
expression of human HLA-A0201 covalently bound to human β2
microglobuline (NSG-HLA-A2/HHD) (Jackson laboratory) (35),
aged from 8 to 12 weeks at the start of the experiments. Bothmale
and female mice were used, and their repartition was balanced
between treatment groups in each cohort. They received a sub-
lethal (2Gy) irradiation (137Cs source gamma-cell irradiator 40,
Nordon, Canada) on day−1, followed on day 0 by an intravenous
(i.v.) injection (lateral tail vein) of 1 or 1.5× 106 PBMCs obtained
from healthy mismatched (non-HLA-A2) volunteers to induce
GVHD. We previously reported that infusion of PBMCs from
non-HLA-A2 donors induced stronger GVHD than injection
of PBMCs from HLA-A2+ donors in NSG-HLA-A2/HHD mice
(31). Hence, in this model, GVHD is both xenogeneic (human
to mouse) and allogeneic (non-HLA-A2 donor to HLA-A2
recipient). We used PBMCs from 3 different donors for the 3
cohorts to account for inter-donor variability (all groups of mice
were transplanted with the same donor within each cohort). Mice
(usually 8 per group) were treated with 3 i.v. injections of BM-,
UC- or AT- MSCs diluted in 200 µL PBS, or the same volume
of PBS (control group) on days 14, 18, and 22. In the second
cohort, one group received i.p. injections of 4mg tocilizumab
(RoActemra R©, Roche) 2 h before each MSC infusion. GVHD
severity was assessed by a scoring system that incorporates four
clinical parameters—weight loss, posture (hunching), mobility
and anemia—each parameter receiving a score of 0 (absent) to
2 (maximum), as previously described (31, 36, 37). Mice were
monitored daily during the experiments and assessed for GVHD
score three times a week. Mice reaching a GVHD score of 6/8
were euthanized in agreement with the recommendation of our
ethical committee. Final scores for animals reaching the limit
score were kept in the data set for the remaining time points
(last value carried forward). Blood samples were collected by tail
puncture at day 28 and day 42 after human cell transplantation
for flow cytometry analysis. If enough blood could be harvested
from mice, cells were counted with a Sysmex XS-800i R©. In the
third cohort, additional blood samples were collected 1 day after
the 2nd MSC infusion for cytokine measurements.
Flow Cytometry
For peripheral blood collected from mice, samples were first
depleted of erythrocytes using RBC lysis buffer (eBioscience,
San-Diego, CA) according to the manufacturer’s instructions.
Cells were stained with various combinations of fluorescence-
conjugated anti-human antibodies. For surface staining, cells
were incubated with surface antibodies for 20min at 4◦C in the
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dark and washed twice with PBS/3% FBS (Lonza). Intracellular
staining was performed by using the FoxP3 Staining Buffer Set
(eBioscience), according to the manufacturer’s instructions. For
intracellular cytokine staining, cells were first stimulated for 4 h
at 37◦C and 5% CO2 in RPMI supplemented with 10% FBS and
in the presence of PMA/ionomycin, brefeldin A and monensin
(Cell Stimulation Cocktail + Protein Transport Inhibitors,
eBioscience), according to the manufacturer’s instructions. Data
were acquired on a FACSCanto II or LSRFortessa flow cytometer
(Becton Dickinson) and analyzed with the Flowjo software
v10.0.7r2 (Tree Star Inc., Ashland, OR). Data from the flow
cytometry analyses of blood samples of mice in the third cohort
were also analyzed with FlowSOM. Data were compensated,
then human CD45+ cells were manually gated with FlowJo
v10, concatenated within the same group and analyzed with the
Bioconductor package FlowSOM.
Cytokine Measurement
Mouse sera were collected with SST Tubes (BD Microtainer),
centrifuged for 10min, then stored at−80◦C. The concentration
of human cytokines was determined after 2-fold serum dilution,
by using a custom Magnetic Luminex Performance Assay (R&D
Systems, USA). Procedures were performed according to the
manufacturer’s instructions. Results were acquired on Bio-
Plex System and analyzed with Bio-Plex Manager Software 4.0
(Biorad Laboratories).
Rotational Thromboelastometry (ROTEM)
MSCs from 3 different healthy donors (2 donors for AT-
MSCs) were thawed and cultured 1 week before the experiment.
Samples of blood from 3 healthy volunteers were collected in
citrated tubes. PBS was used as a negative control. MSCs were
incubated 10min in citrated whole blood at a concentration of
106 cells/ml, then CaCl2 (Star-TEM) was added to the sample
and measurements of coagulation activation was made using
ROTEM R© (NATEM assay) according to the manufacturer’s
procedure. Samples were kept at 37◦C during the procedure.
Statistical Analyses
Data are presented as individual observations (with or without
median) or as median with range. For survival analyses,
comparisons between groups were made with the log-rank test
and with multivariate Cox models adjusted for experiment
(one donor PBMC was used per experiment), mouse gender
and mouse weight at transplantation. Survival curves were
plotted using Kaplan-Meier estimates. Evolution of GVHD scores
over time was analyzed with a repeated ordinal logistic model
(GENMOD), with adjustment for experiment, mouse gender, and
mouse weight at transplantation. GVHD score at death were
carried forward after death. For in vivo analyses, comparisons
between control group and either BM-MSC, UC-MSCs, or AT-
MSC groups were made with one-way analysis of variance
tests with Dunnett’s post-hoc procedure. Analyses were adjusted
for experiment. For in vitro analyses, comparisons between
control group and either BM-, UC-, or AT-MSC groups were
made using repeated measure one-way analysis of variance test
with Dunnett’s post-hoc procedure (except for inhibition of
lymphocyte proliferation: comparisons between BM-, UC-, and
AT-MSC groups were made using repeated measure one-way
analysis of variance test with Bonferroni post-hoc procedure)
and comparisons between resting and primed MSC groups were
made with paired t-tests. To normalize their distribution, some
variables underwent prior logarithmic transformation. Results
were considered significant at the 5% level (p < 0.05). Statistical
analyses were carried out with RStudio v1.1.453 and Graphpad
Prism 5.0 (Graphpad Software, USA).
RESULTS
Impact of MSCs on PBMC Proliferation
in vitro
We compared the ability of MSCs to suppress PBMC
proliferation in vitro at two different MSC/PBMC ratios (1/5 and
1/10). Lymphocytes were stimulated with anti-CD3/CD28 beads,
mimicking stimulation by APCs as well as early events occurring
in human PBMCs infused in NSG-HLA-A2/HHDmice (31). We
repeated the experiment with MSCs from 2 to 3 different donors
and PBMCs from 2 to 4 different donors for each MSC donor.
Some of these experiments were realized in triplicate, and mean
values were used for statistical analysis. BM-, UC-, and AT-MSCs
were either resting or primed (BM∗, UC∗, and AT∗) by IFNγ and
TNFα. This is relevant since previous reports have demonstrated
that these cytokines have a profound impact on MSCs (38–42)
and since high levels of IFNγ and TNFα are present in the sera
of NSG-HLA-A2/HHD mice infused with human PBMCs (31).
The impact of MSCs on PBMC proliferation was calculated as
percentage suppression compared with the proliferative response
in the positive control without MSCs.
After 72 h of co-culture, resting BM- and AT- MSCs were
more potent to inhibit PBMC proliferation compared to resting
UC-MSCs at a ratio of 1/5 (median inhibition 51 vs. 48 vs.
9%, p = 0.0001) and 1/10 (median inhibition 30 vs. 27 vs.
3%, p = 0.0005) (Figure 1). As previously observed, BM-,
AT- and UC-MSCs primed with IFNγ and TNFα were more
potent to inhibit PBMC proliferation than resting MSCs at both
MSC/PBMC ratios. Interestingly, primed MSCs from various
origins had a comparable potency to inhibit PBMC proliferation
(Figure 1). These data suggest that, in the context of CD3/CD28
stimulation, PBMC proliferation is potently inhibited by BM-,
UC-, and AT-MSCs primed with IFNγ and TNFα. Without that
inflammatory priming, only BM- and AT-MSCs inhibited PBMC
proliferation at these low MSC/PBMC ratios.
Impact of MSCs on Lymphocyte Activation
in vitro
We also analyzed the effects of BM-, UC-, and AT-MSCs on
lymphocyte activation in vitro. PBMCs were cultured withMSCs,
either resting (BM, UC, and AT-conditions) or primed with IFNγ
and TNFα (BM∗, UC∗, and AT∗ conditions), or without MSCs
(control condition), at a MSC/PBMC ratio of 1/10. Expression of
early (CD69), late (CD25) and very late (HLA-DR) markers of
activation of CD4+ and CD8+ cells was analyzed after 6, 24, 48,
72, and 96 h. The experiment was repeated twice with MSCs and
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FIGURE 1 | Inhibition of lymphocyte proliferation in vitro. PBMCs were cultured with or without MSCs in the presence of anti-CD3/CD28 microbeads for 3 days, at
MSC/PMBC ratios of 1/5 and 1/10. Proliferation of PBMCs was assessed using a CellTrace CFSE Cell Proliferation Kit. The effect of MSCs on PBMC stimulation
responses was calculated as percentage suppression compared with the proliferative response in the positive control without MSCs. For inflammatory stimulation,
MSCs were incubated with IFNγ 10 ng/ml and TNFα 15 ng/ml during 40 h, prior to harvest (BM*, AT*, and UC*). (A) Representative plots of PBMC proliferation in
coculture with MSCs, assessed by CFSE dilution. (B) Inhibition of lymphocyte proliferation. Data are presented as individual observations (or mean value if the
experiment was realized in triplicates). White, light, and dark symbols represents MSCs from different donors; each point represents a different MSC-PBMC couple.
Differences between resting MSC groups and between primed MSC groups are calculated with repeated measure ANOVA with Bonferroni post-hoc procedures (only
results with Bonferroni post-hoc tests are represented). Differences between resting and primed MSC groups were calculated with paired t-test (*p < 0.05, **p <
0.01; ***p < 0.001).
PBMCs from 2 different donors. The kinetics of PBMC activation
by anti-CD3/CD28 beads resulted, as previously described (43),
in a rapid and brief upregulation of the early activation marker
CD69 within 24 h, followed by a rapidly progressive and lasting
expression of CD25, and a slowly progressive upregulation of
HLA-DR (Supplementary Figure 1).
There was no major impact of MSCs on the kinetics of CD69
and CD25 expression on T cells except for a higher expression of
CD69 in AT-MSC conditions at 96 h (Figures 2A–D). In contrast,
HLA-DR up-regulation on both CD4+ and CD8+ lymphocytes
was clearly impacted by MSC co-culture. Specifically, compared
to the control condition, HLA-DR expression on CD4+ cells
was significantly lower in the BM condition at 24, 72, and 96 h
and in UC and AT conditions at 24, 48, 72, and 96 h. The
effect of MSC coculture on CD8+ cells was less pronounced
but was still observed at the latest assessed time point (96 h)
(Figures 2E–G). Interestingly, priming of BM-MSCs with IFNγ
and TNFα resulted in an early upregulation of HLA-DR on both
CD4+ and CD8+ T cells, while this effect was not observed with
primed UC- or AT-MSCs (Figures 2E,F).
Taken together, these data suggest that UC- and AT-MSCs
exert a potent inhibitory effect on lymphocyte activation
regardless of inflammatory priming, while BM-MSCs
elicit transient lymphocyte activation when primed by
inflammatory cytokines.
Impact of MSCs on T Helper Subsets in
vitro
We also studied the impact of MSC co-culture on lymphocyte
subset proportions in vitro. We analyzed the effect of BM-, UC-,
and AT-MSCs on T helper subset proportions when PBMCs
were cultured with anti-CD3/CD28 beads, at a MSC/PBMC
ratio of 1/10, for 7 days. For Treg (CD4+CD25+FoxP3+)
subset analyses, we added IL-2 in the culture media. The
experiment was repeated three times with MSCs and PBMCs
from 2 to 4 different donors, and we analyzed the expression of
CD25+ and FoxP3+ as well as IL-10, IFNγ, IL-4, and IL-17 at
day 7 (Supplementary Figure 2).
Co-culture of PBMCs with MSCs increased the percentage
of CD4+CD25+FoxP3+ cells (Tregs) at day 7 compared
to controls. This reached statistical significance with UC-
and AT-MSCs (Figure 3A). Coculture of PBMCs with
BM- and AT-MSCs increased the proportion of IL-10+
CD4+ cells (respectively median 6.8 and 6.5 vs. 3.3%
in control condition) (Figure 3B). The proportions of
Th1 (IFNγ+CD4+) and Th2 (IL4+CD4+) cells were
not significantly impacted by MSC coculture compared
to the control condition (Figures 3C,D). However, the
percentage of Th17 (IL17+CD4+) cells was lower when
PBMCs were cultured with UC-MSCs compared to
controls (Figure 3E).
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FIGURE 2 | Lymphocyte activation (measured by CD69, CD25, and HLA-DR expression) in co-culture with MSC. PBMCs were cultured with or without MSCs in the
presence of anti-CD3/CD28 microbeads for 4 days, at a MSC/PBMC ratio of 1/10. For inflammatory stimulation, MSCs were incubated with IFNγ 10 ng/ml and TNFα
15 ng/ml during 40 h, prior to harvest (BM*, AT*, and UC*). Expression of (A,B) CD69, (C,D) CD25, and (E,F) HLA-DR on CD4+ and CD8+ lymphocytes was
analyzed after 6, 24, 48, 72, and 96 h by FACS. (G) Representative plots of HLA-DR expression at H96 in CD4+ and CD8+ lymphocytes. Data are presented as
median with range. Differences between control, and BM, AT, or UC groups are calculated with repeated measure ANOVA with Dunnett’s post-hoc procedures (only
results of Dunnett’s post-hoc tests are represented). Differences between resting and primed MSC groups were calculated with paired t-test (*p < 0.05, **p < 0.01;
***p < 0.001).
In summary, co-culture of PBMCs with BM-MSCs increased
the proportion of IL10+CD4+ cells, while UC-MSCs resulted in
a higher Treg proportion and lower Th17 proportions, and AT-
MSCs increased both Tregs and IL10+CD4+ cells proportions.
Impact of MSC Therapy on GVHD in
Humanized Mouse Model
Mice received sub-lethal (2Gy) irradiation on day−1, followed
by an i.v. injection of PBMCs obtained from healthy mismatched
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FIGURE 3 | T-helper lymphocyte subsets in co-culture with MSC. PBMCs were cultured with or without MSCs in the presence of anti-CD3/CD28 microbeads (and
IL-2 for Treg analyses) for 7 days, at a MSC/PBMC ratio of 1/10. Proportions of (A) Treg (CD4+CD25+FoxP3+), (B) IL10+, (C) Th1 (IFNγ+), (D) Th2 (IL-4+), and (E)
Th17 (IL-17+) cells were evaluated at day 7 by FACS. Data are presented as individual observations (or mean value if the experiment was realized in duplicates) with
median. Global p-values (repeated measure ANOVA-1) are shown as well as comparisons between MSC groups and controls with Dunnett’s post-hoc procedure
(*p < 0.05; **p < 0.01).
volunteers (non-HLA-A2) on day 0, and 3 i.v. injections of BM-
MSCs (BM group), UC-MSCs (UC group), or AT-MSCs (AT
group) in 200 µL PBS, or the same volume of PBS alone (control
group) on days 14, 18, and 22 (8 mice per group per experiment).
In order to prevent inter-donor variability, the experiment was
replicated three times with three different donors.
In the first cohort, mice received 1× 106 PBMCs, resulting in
the development of an acute GVHD that was lethal in all control
mice. We started to infuse MSCs (1 × 106 MSCs/dose/mouse)
or PBS at day 14, when mice showed the first signs of GVHD.
Control mice started to die 15 days after the 3rd infusion (from
day 39). We observed an earlier mortality in the MSC groups,
especially in the AT group in which one mice died at the time
of the third MSC infusion, probably of pulmonary embolism
(although no necropsy was performed to prove it). However, UC-
MSC therapy eventually resulted in a trend for a longer median
survival (63 vs. 44, 49, and 43 days in the control, BM and AT
groups, respectively, ns) (Figure 4A).
Given the results of the first cohort, we elected to slightly
increase the number of PBMCs infused in order to induce a
stronger GVHD. Further, we elected to increase the MSC dose
to 2 × 106 MSC/dose/mouse, except for the UC groups in
which we compared 1 and 2 × 106 MSC/dose/mouse (UC1 and
UC2 groups). Mice received 1.5 × 106 PBMCs from another
donor and developed GVHD that was lethal (from day 17) in
approximately 75% of the mice. Further, since we had observed
high serum human IL-6 levels following MSC infusion in NSG
mice in a prior study (44), we also assessed the impact of an
i.p. injection of 4mg tocilizumab, an anti-human IL-6 receptor
antibody, 2 h before each MSC injection, in a sixth group of mice
treated with 2× 106 UC-MSCs (UC2-T group). Unfortunately, as
observed in the first cohort of mice, AT-MSCs induced injection-
related mortality in 3 mice. Specifically, following the first AT-
MSC injection on day 14, the 2nd mice receiving 2 × 106
AT-MSCs died of probable pulmonary embolism (unfortunately
no necropsy was performed to confirm pulmonary embolism);
hence the 6 remaining mice received 1 × 106 AT-MSCs. After
the second injection, the 2 first mice given 2 × 106 AT-MSCs
died of probable pulmonary embolism; hence the 5 remaining
mice received 1 × 106 AT-MSCs for the second and the third
injections, and there was no further acute mortality. Focusing
on BM- and UC- MSCs, MSC therapy slightly delayed GVHD
onset and increasedmedian survival, but survival curves were not
statistically different (median survival of 42, 59, and 59 days in
the control, BM and UC2 groups, respectively). No dose effect
was observed since survival was similar between mice treated
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FIGURE 4 | Impact of MSC therapy on GVHD. After 2Gy total body irradiation, NSG-HLA-A2 mice were transplanted on day 0 with 1–1.5 × 106 PBMCs and treated
with 3 i.v., injections (arrows) of 1–2 × 106 MSCs derived from either BM, UC, or AT, or with PBS (control group) on days 14, 18, and 22. (A) Survival curves of mice
from the 1st cohort (1 × 106 PBMCs − 1 × 106 MSCs); n = 8 mice per group. (B) Survival curves of mice from the 2nd cohort (1.5 × 106 PBMCs − 2 × 106 MSCs
in BM, AT, and UC2 groups, 1 × 106 MSCs in UC1 group — IP infusions of tocilizumab in UC2-T group); n = 8 mice per group. (C) Survival curves of mice from the
3rd cohort (1 × 106 PBMCs − 1 × 106 MSCs); n = 8 mice per group. (D–F) GVHD scores of mice from cohorts 1, 2, and 3 (data shown as means).
with 1 or 2 × 106 UC-MSCs (median survival 61 vs. 59 days,
respectively). Finally, the adjunction of tocilizumab failed to
enhance the efficacy of UC-MSC therapy (median survival 49 vs.
59 days in the UC2-T and UC2 groups, ns) (Figure 4B).
Given the high proportion of AT-MSC mice dying from MSC
infusions, we elected to focus on BM-MSC and UC-MSC in
the third cohort. Mice received 1 × 106 PBMCs from a third
donor which induced this time a relatively mild GVHD. They
were treated with 1 × 106 BM- or UC-MSCs, or the same
volume of PBS alone (control group) on days 14, 18, and 22,
as in the first cohort. Only 4 of the 24 mice died of GVHD
(1, 1 and 2 in the control, BM and UC groups, respectively).
One mouse in the control group died on day 6 of unexplained
cause without sign of GVHD, and another mouse died right after
the 2nd UC-MSC injection, probably of pulmonary embolism
(Figure 4C). Blood samples were collected on day 19 (1 day after
the second MSC infusion) and serum levels of human IL-6, IL-
10, IFNγ, and TNFα were analyzed by Bio-Plex. We observed
slightly higher human IL-6 serum levels in mice treated with
UC-MSCs compared to controls, but not in mice treated with
BM-MSCs (median 0.0, 0.4, and 3.2 pg/ml in the control, BM
and UC groups, respectively). No differences in serum levels
of human IFNγ (a marker of GVHD severity), TNFα and IL-
10 were observed between the 3 groups at this early time-point
(Supplementary Figure 3).
In order to further assess the impact of BM-MSCs or UC-
MSCs onGVHD in the 3 cohorts combined, we built a Coxmodel
adjusted for experiment (donor), mouse gender and mouse
weight.We elected not to include AT-MSCs in themodel given its
high rate of injection-related mortality. We did not either include
the data from the UC-Tocilizumab group. The multivariate
model confirmed that intravenous MSC infusions failed to
significantly increase survival (hazard ratio [HR] = 0.59, 95% CI
0.32–1.08; P = 0.087) (Supplementary Table 1). In a sensitivity
analysis using the same adjustments as described above, we
compared survival in control vs. eachMSC group separately. The
results for the BM-MSC vs. control comparison was HR = 0.63
(95% CI 0.30–1.34, P = 0.24) while the figures for the UC-
MSC vs. control comparison was HR = 0.56 (95% CI 0.28–1.10,
P = 0.09) (Supplementary Table 2). In concordance with these
results, GVHD scores were not significantly lower in the MSC
than in control mice (generalized estimating equation [GEE]
estimate−0.7, 95% CI−1.8–0.3, P = 0.18) (Figures 4D–F).
Characterization of Circulating Human
Lymphoid Cells in Mice Treated With MSCs
We also analyzed circulating human lymphocytes in the
peripheral blood of mice on days 28 and 42 post-transplantation.
Proliferation of human lymphocytes was not significantly
influenced by MSC therapy, as percentages of human CD45+
lymphoid cells, CD4/CD8 ratio and expression of Ki67 in
CD4+ and CD8+ cells, were not significantly different in MSC
groups compared to the control group (Supplementary Figure 4
including data from the 3 cohorts).
We also analyzed the impact of MSC therapy on Treg
proportions (in all 3 cohorts) and intracellular cytokine
expression in conventional (non-Treg) CD4+ (Tconv) and CD8+
cells (in cohorts 2 and 3). Treg frequencies remained low in
all groups, although they were possibly slightly higher in the
UC-MSC group on day 28 after transplantation (Figure 5A and
Supplementary Figure 5). On day 28, there was also a trend
toward a higher expression of IL-10 in CD8+ T cells (but not in
CD4+ T cells) in the BM group (median 5.4% vs. 2.7 and 2.3% in
the control and UC groups). On day 42, we observed a significant
increase in the percentages of IL-10+ CD4+ and IL-10+ CD8+
cells in the BM group compared to the control group (IL-10+
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FIGURE 5 | Circulating human lymphoid cell subsets in peripheral blood of mice on days 28 and 42 after transplantation. After 2Gy total body irradiation,
NSG-HLA-A2 mice were transplanted on day 0 with 1–1.5 × 106 PBMCs and treated with 3 i.v. injections of 1–2 × 106 MSCs derived from either BM or UC, or with
PBS (control group) on days 14, 18, and 22. Peripheral blood samples were collected on days 28 and 42 after transplantation for flow cytometry analyses, including
analyses of the proportions of (A) Tregs (CD25+FoxP3+) among CD4+ cells, (B,C) human Tconvs and CD8+ cells expressing IL-10, (D–E) human Tconv and CD8+
cells expressing IFNγ, and (F) human Tconv expressing IL-17. Data are presented as individual observations with median. Light, medium, and dark-colored symbols
represent cohorts 1, 2, and 3, respectively, with empty symbols representing the lower dose UC group of the 2nd cohort. Global p-values (adjusted for experiment) are
shown as well as comparisons between MSC groups and controls with Dunnett’s post-hoc procedure (*p < 0.05). Prior logarithmic transformation was applied for
Tregs on days 28 and 42, and for IL10+Tconv and IL10+CD8+ cells on day 42.
CD4+: median 3.5 vs. 1.2%; IL-10+ CD8+: median 4.4 vs. 1.4%)
(Figures 5B,C).
We also analyzed the impact of MSC therapy on pro-
inflammatory IFNγ and IL-17 secreting cells (in cohorts 2 and
3). There was no significant impact of MSC therapy on the
proportion of Th1 (IFNγ+ Tconv) cells on days 28 and 42
post-transplantation (Figure 5D and Supplementary Figure 5).
We observed a higher proportion of IFNγ+ CD8+ cells in
the BM group compared to the control group on day 28
post-transplantation (median 91 vs. 85%), while no significant
difference was observed on day 42 (Figure 5E). We also observed
a trend toward a higher proportion of Th17 (IL17+Tconv) cells in
the BM group on day 28 (median 4.7 vs. 3.1 and 2.1% in control
and UC groups, respectively), but no significant difference on
day 42 post-transplantation (Figure 5F). Finally, there was no
difference in the proportions of CD4+ and CD8+ cells expressing
TNFα or IL-2 (Supplementary Figure 5).
Overall, these data suggest that UC-MSC therapy resulted in
a trend toward a higher percentage of Tregs that nevertheless
remained infrequent. BM-MSC therapy was associated with
higher proportions and absolute numbers of IL-10+ cells, and
also with a trend toward higher percentages of Th17 and
IFNγ+CD8+ cells.
In vitro Impact of MSCs on Coagulation
In our in vivo studies, several mice died right after IV injection
of MSCs, mostly AT-MSCs (4 mice), but also UC-MSCs (1
mouse). Since the procoagulant activity of MSCs has been
described (45) and since death by pulmonary embolism has
been reported in MSC-injected mice (46, 47), we compared the
procoagulant activity of MSCs of the 3 origins by performing
rotational thromboelastometry (ROTEM). We used PBS as
negative control. The experiment was repeated 3 times with
MSCs from 2 donors and blood from 3 other healthy donors.
We measured clotting time (CT; time from test start until a
clot firmness amplitude of 2mm is reached), clot formation
time (CFT; time between 2 and 20mm amplitude of the
clotting signal), maximum clot firmness (MCF) and α-angle
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FIGURE 6 | Rotational thromboelastometry (ROTEM) with blood incubated with MSCs. MSCs derived from BM, UC, or AT were incubated 10min in citrated whole
blood at a concentration of 106 cells/ml, then CaCl2 (Star-TEM) was added to the sample and measurements of coagulation activation were made using ROTEM
®
(NATEM assay). Data are presented as individual observations with median. Global p-values (repeated measure ANOVA-1) are shown as well as two-by-two group
comparisons with Bonferroni post-hoc procedure (*p < 0.05; **p < 0.01; ***p < 0.001).
(angle between the baseline and a tangent to the clotting curve
through the 2mm amplitude point). We observed that BM-
MSCs significantly reduced the clotting time when added to
whole blood, but not as much as AT and UC-MSCs (median
831, 477, 117, and 92 s in the control, BM, AT, and UC groups,
respectively). Similarly, we observed a shorter clotting formation
time and a higher maximum clot firmness with AT and UC-
MSCs compared to controls (median CFT 325, 203, 91, and
97 s and median MCF 45, 53, 61, and 62mm in the control,
BM, AT, and UC groups, respectively), with a significantly
increased α-angle compared to control and BM-MSCs (median
α-angle 40, 53, 72, and 71◦ in the control, BM, AT and UC
groups, respectively) (Figure 6). These results show stronger
coagulation activation by AT- and UC-MSCs compared to BM-
MSCs. These data suggest that the higher mortality observed
after AT-MSC infusion compared to UC-MSC infusion is the
result of not only a higher induction of coagulation. Cell
size and/or different expression of adhesion molecules might
be involved.
DISCUSSION
Fifteen years after the first publication of a clinical success ofMSC
therapy in acute GVHD by Le Blanc et al. (48), the controversy
about their efficacy still remains. The complexity of the
mechanisms of action of MSCs, as well as their heterogeneity and
plasticity depending on many factors such as their origin, culture
conditions, or inflammatory environment, combined with the
complex pathophysiology of GVHD and the heterogeneity
of administration protocols and patient characteristics have
contributed to the discrepancies between studies. Most clinical
trials have used BM-MSCs, but fetal tissue-derived MSCs have
the advantage of being readily available and easy to collect
from a waste product. Moreover, even though they share
many biological characteristics, MSCs from different origins
differ in several instances, including phenotype, secreatome, or
immunomodulatory properties. MSC from alternative origins
might therefore be a better option than BM-MSCs in GVHD.
In this study, we compared the efficacy of BM-, AT- and
UC-MSCs injected at day 14, 18, and 22 post-transplantation
in a model of mixed xenogeneic and allogeneic GVHD in
NSG-HLA-A2 mice (31). Indeed, although important differences
remain between GVHD in humanized NSGmousemodels and in
humans (such as the GVHD-target organs, the lack of interaction
between some mouse cytokines and human cells, or the absence
of donor APC engraftment in the NSGmouse model), important
key mechanisms of GVHD pathogenesis are shared in human
and xenogeneic GVHD. These include expansion of T-cell clones
that recognize genetic disparities with the recipient (including
murine MHC and human HLA-A2 in our model) following
activation of their TCR and co-stimulation with host APCs. This
results in upregulation of IL-2/STAT5, mTOR and Aurora kinase
A pathways, and differentiation toward effector T cells able to
secrete high amounts of TNFα and IFNγ (31). Further, in contrast
to mouse-to-mouse models of GVHD, humanized NSG(-HLA-
A2) models take into consideration donor genetic diversity when
different PBMC donors are used. We elected to infuse 1 ×
106 or 1.5 × 106 PBMCs from non-HLA-A2 donors following
2Gy irradiation, since we previously reported that infusion of 1
× 106 PBMCs from non-HLA-A2 donors induced a moderate
GVHD in that model while administration of 2 × 106 PBMCs
resulted in very severe GVHD (31). Indeed, infusion of the same
dose of PBMCs from non-HLA-A2 donors consistently results in
dramatically worse GVHD in NSG-HLA-A2 than in NSG mice
(in which 2× 106 to 5× 106 PBMCs are usually infused to induce
GVHD when NSG mice are previously irradiated (31, 49–52).
While the PBMC dose infused appeared adequate for experiment
(donor) #1 and #2, it was suboptimal with the donor for the 3rd
experiment since most of the control mice it that group survived
beyond day 90.
The main observation of our study was that MSC infusions
failed to significantly prevent GVHD-related mortality. We
cannot exclude that this was due to the sample size since the
HR for mortality was in favor of (UC- and BM-) MSC therapy.
However, the number of mice studied (a total of 24 control and 56
UC- or BM-MSCmice) was quite decent and several anti-GVHD
prevention strategies proved to be efficient in NSG (36, 49, 53) or
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NSG-HLA-A2 mice (53) using fewer mice per arm. Interestingly,
despite their different in vitro ability to inhibit T cells, we did not
observe significant differences in term of GVHD prevention by
BM-, UC- or AT-MSCs. However, one may argue that UC-MSCs
appear more efficient than BM-MSCs while the efficacy of AT-
MSCs was difficult to establish since several mice died of probable
pulmonary embolism immediately after injection.
The dose and timing of infusion can always be discussed.
However, we do not believe that the MSC dose was insufficient,
since we infused a much higher dose of MSCs per kilogram
compared to human studies, and since no differences were
observed between the two UC-MSC dose groups in the second
cohort. Although one could argue that the dose of MSC infused
might have been too high, prior experimental studies have
demonstrated better GVHD control with higher doses of MSC
administered (54, 55). We elected to infuse MSCs from day 14,
when mice showed the first signs of GVHD. Indeed, several
previous studies showed the inefficacy of resting unmanipulated
MSCs when infused before GVHD onset, while IFNγ primed
MSCs prevented GVHD (39, 56). We hypothesized that the high
circulating levels of TNFα and IFNγ on day 14 in the NSG-HLA-
A2 model (31) could activate MSCs in vivo and increase their
efficacy (as observed in vitro). Although starting MSC injection
at day 14 might have been too late to prevent the aggressive and
already engaged GVHD process, most trials of MSC therapy for
acute GVHD have included patients in active (mostly steroid-
refractory) acute GVHD.
Several prior articles have assessed the ability of BM- or cord
blood (CB)-MSC to prevent or treat xenogeneic GVHD, although
none compared the different MSC sources (44, 55–62) (Table 1).
These studies differ in terms of source of MSC, schedule of MSC
infusion as well as type/number/route of injection of human
PBMCs. While some observed longer survival with MSCs (61),
several others failed to demonstrate a significant benefit of MSCs
as treatment of xenogeneic GVHD, as observed in the current
study (44, 57).
Another observation of our in vivo studies was that
intravenous infusion of 1 × 106 UC-MSCs was followed by a
peak of serum IL-6 while infusion of the same number of BM-
MSCs did not. Our team previously showed that an i.p. infusion
of 3 × 106 BM-MSCs resulted in a peak of serum IL-6 (44),
but it is possible that the rise in IL-6 following the infusion of a
smaller amount of MSCs did not reach the detection limit of the
technique. This finding is consistent with several in vitro studies
that have demonstrated a higher secretion of IL-6 from UC-
MSCs compared to BM-MSCs (63). Unfortunately, co-treatment
with the anti-IL6R tocilizumab did not improve survival in mice
treated with UC-MSCs, suggesting that this pro-inflammatory
signal following UC-MSC infusions does not lessen their efficacy.
Flow cytometry analyses performed at day 28 post-
transplantation revealed a trend toward an increased proportion
of Tregs in mice treated with UC-MSCs, while BM-MSC
therapy was associated with an increased proportion of IL10+
lymphocytes, but also a trend toward an increased proportion
of Th17 cells [whose role in xenogeneic GVHD in humanized
mouse models is increasingly demonstrated (37, 64)] and
IFNγ+CD8+ cells. Most of these differences were lost at day 42,
confirming the limited long-term effects of MSC therapy in this
GVHD model. However, a survival bias cannot be ruled out.
Further, it should be emphasized that Treg frequencies, even in
UC-MSC mice, remained low (in the range of 2.5%) compared
to what has been achieved in this model with Treg-promoting
therapies such as azacitidine (53).
In in vitro co-culture, we observed that resting BM- and AT-
MSCs inhibited PBMC proliferation induced by anti-CD3/CD28
beads more potently than resting UC-MSCs. However, UC-
MSC efficacy was significantly enhanced by priming with IFNγ
and TNFα. Lymphocyte proliferation was inhibited by primed
BM- and AT-MSCs to a little higher extent than by primed
UC-MSCs, but the difference was not statistically significant.
Conflicting results have been reported in the literature about
the relative potency of BM-, AT- and UC-MSCs to inhibit T-
cell proliferation, which seems to depend on the proliferative
stimulus and priming of MSCs (65–67). In our murine model,
this ability to inhibit lymphocyte proliferation did not translate
into a reduction of CD45+ cell chimerism or Ki67 expression
in CD4+ and CD8+ cells in MSC groups compared to controls,
possibly because MSCs were infused after the early T-lymphocyte
expansion phase. Similarly, a study in patients showed that
Ki67 expression by lymphocytes was not modulated by MSC
infusion (68).
MSCs also modulate the lymphocyte activation status. In
a retrospective study on BM-MSC therapy for GVHD, MSC-
treated patients had lower proportions of HLA-DR+CD4+ cells
at day 90 and of HLA-DR+CD8+ cells at day 180 post-
MSC infusions (68). We studied lymphocyte activation by anti-
CD3/CD28 beads in co-culture with MSCs, and observed that
UC- and AT-MSCs, whether resting or primed with IFNγ and
TNFα, induced the most potent down-regulation of HLA-DR on
CD4+ and CD8+ cells. Importantly, co-culture of PBMCs with
primed BM-MSCs resulted in a higher expression of the early
activation marker CD69 and in a rapid upregulation of HLA-DR
24 h after activation of PBMCs. Similarly, other authors reported
an early and transient upregulation of the co-stimulatory
receptor CD28 on PHA-stimulated lymphocytes in co-culture
with IFNγ-primed BM-MSCs but not with resting BM-MSCs
or either resting or primed UC-MSCs (67). Therefore, unlike
UC- and AT-MSCs, BM-MSCs in an inflammatory environment
seem to induce a rapid pro-inflammatory reaction in contact with
PBMCs before exerting their immunosuppressive properties.
Accordingly, we observed at day 28 a higher expression of HLA-
DR on Tconv cells in the BM group compared to the UC group
in the third cohort.
The effects of MSCs on T lymphocytes are thought to
combine not only suppression of pro-inflammatory cells but
also induction of Tregs. In a retrospective study, BM-MSC
treated patients had a higher proportion of Tregs at days 30
and 90 and of IL10+CD4+ cells at day 90, a lower percentage
of Th17 cells at day 30, and a lower serum IFNγ/IL-4 ratio
(68). As mentioned above, in our murine model there was a
trend toward a higher proportion of Tregs with UC-MSCs,
while BM-MSCs induced higher levels of IL10+CD4+ cells,
but also tended to induce higher levels of Th17 cells. This
is consistent with our observation that, in vitro, UC-MSCs
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TABLE 1 | Main prior studies of MSC as prevention/treatment of xenogeneic GVHD.
References Xenogeneic mouse
model




Tisato et al. (57) NOD/SCID, TBI 2.5Gy,
20 × 106 hPBMCs IV
3 × 106 CB-MSCs IV, day 0 No change in weight loss and human T-cell expansion.
3 × 106 CB-MSCs IV, days 0, 7, 14, and 21 Decreased T-cell expansion, no GVHD development.
Gregoire-Gauthier
et al. (58)
NSG, TBI 3Gy, 10 × 106
hPBMCs IP
1 × 106 CB-MSCs IV, day 0 Significant increase in survival and reduction of clinical signs
of GVHD.
Bruck et al. (44) NOD/SCID, TBI 3Gy +
aASGM1 Ab IP, 200 × 106
hPBMCs IP
2 × 106 BM-MSCs IV or IP, day 0 No significant increase in survival.
NSG, TBI 2.5Gy, 30 × 106
hPBMCs IP
3 × 106 BM-MSCs IP, days 0, 7, 14, and 21 Slight survival advantage.
3 × 106 IFNγ-BM-MSCs IP, days 0, 7, 14,
and 21
No significant increase in survival.
3 × 106 BM-MSCs IV, days 0, 7, and 14 No significant increase in survival.
Tobin et al. (56) NSG, TBI 2.4Gy, 6.3 × 105
hPBMCs/g BW
4.4 × 104 BM-MSCs/g BW, IV, day 7 Increased survival, reduction of liver and gut pathology.
4.4x104 IFNγ-BM-MSCs/g BW, IV, day 0 Increased survival, reduced liver and gut pathology, and
serum level of TNFα.
Jang et al. (59) NSG, TBI 2Gy, 1 × 106
hPBMCs IV
5 × 105 CB-MSCs IV, day 0 or days 0, 7,
and 14
No significant increase in survival.
5 × 105 CB-MSCs IV, days 0, 3 and 6 Increased survival, reduced tissue damage, lymphocyte




TBI 4Gy, 15 × 106
hPBMCs IV
0.5 × 106 UC-MSCs IV, day 8 No significant increase in survival.
2 × 106 UC-MSCs IV, day 8 Trend toward a longer survival.
0.5 × 106 rapamycin-UC-MSCs IV, day 8 Increased survival, lower proportion of human cells in the
spleen.
Kim et al. (60) NOD/SCID, TBI 3.2Gy,
20 × 106 hPBMCs IV
1 × 106 BM-MSCs (normoxia or 1% O2) IV,
days 0 and 7 or days 0, 3, and 6
Increased survival, reduced GVHD symptoms (no difference
between normoxia and hypoxia).
TREATMENT
Tisato et al. (57) NOD/SCID, TBI 2.5Gy,
20 × 106 hPBMCs IV
3 × 106 CB-MSCs IV 4 times every 3 days at
GVHD onset
No change in weight loss and human T-cell expansion.
Jang et al. (59) NSG, TBI 2Gy, 1 × 106
hPBMCs IV
5 × 105 CB-MSCs IV, either day 18, days 18,
21 and 24, or days 18, 25, and 32
Increased survival, reduced weight loss, clinical scores, tissue
damage, and lymphocyte infiltration.
Amarnath
et al. (61)
NSG, 5 × 106 Th1 cells +
3 × 106 monocytes IV
2 × 106 BM-MSCs IV, days 22, 26, and 30 Increased survival, reversal of cutaneous GVHD and weight
loss, decreased proportion of human Th1 cells in the spleen.
Ma et al. (62) NOD/SCID, CY + aASGM1
Ab IP, 10 × 106 hPBMCs IV
1 × 106 placenta-derived MSCs IV, day 11 Increased survival, reduced weight loss, reduced lung and
intestinal damage, increased serum level of TGFβ, decreased
serum level of IL-6 and IL-17, reduced Th17/Tr1 ratio in
spleen and liver.
NOD/SCID, Non-obese diabetic/severe combined immunodeficiency; TBI, total body irradiation; hPBMCs, human peripheral blood mononuclear cells; IV, intravenous; CB, cord blood,
MSCs, mesenchymal stromal cells; GVHD, graft- vs.-host disease; aASGM1 Ab, anti-asialo GM1 antibody; IP, intraperitoneally; BM, bone marrow; NSG, NOD-scid IL-2Rγnull; IFN,
interferon; g BW, gram of body weight UC, umbilical cord; Th1, T helper 1; CY, Cyclophosphamide; Tr1, type 1 regulatory T cells (CD4+ IL10+).
most efficiently induced Tregs and inhibit Th17 cells, while
BM-MSCs induced higher proportions of CD4+IL10+ cells.
AT-MSCs induced both Tregs and CD4+IL10+ cells. We also
observed a lower proportion of Th1 cells on day 28 in mice
treated with UC-MSC in the 3rd cohort. Direct comparisons
of the effects of MSCs of different origins on T-lymphocyte
subsets are scarce (29). UC-MSCs were shown to induce Tregs
more potently than BM-MSCs in vitro (69) or to the same
extent in a rat model of sepsis (70). MSCs could also induce
other types of regulatory T cells although conflicting data have
been reported concerning the mechanisms involved (71) and the
comparison between BM- and UC-MSCs (67, 72). Regarding
Th17 cells, most studies demonstrated a suppressive effect of
MSCs, but no comparison between BM-, UC- and AT-MSC
potency has been reported. We did not observe a reduction
in the proportion of CD4+ cells secreting IFNγ in co-culture
with MSCs in this experimental setting. This is consistent with
prior observations by De Witte et al. who observed a decrease
in the percentage of CD4+ T cells containing intracellular IFNγ
only at higher MSC/PBMC ratios (73), while Ribeiro et al.
observed an upregulation of T-bet mRNA with BM-, UC- and
AT-MSCs (74).
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Finally, we also demonstrated that BM-MSCs are far less
procoagulant thanUC- and AT-MSCs. However, despite a similar
activation of coagulation in vitro, UC-MSCs resulted in only
1 death after infusion in mice, while 4 mice infused with AT-
MSCs died, suggesting that other factors than their potential to
activate coagulation may be involved. Cell size and expression of
adhesion receptors are key factors in pulmonary cell trapping, so
the higher size of AT-MSCsmight be at least partially responsible.
Similar results have been observed with murine AT-MSCs (46)
and human decidual stromal cells (DSCs) (47). In humans, while
BM-MSCs have demonstrated their safety, there are a few cases of
thrombotic events following infusions of AT-MSCs (75). MSCs
activate coagulation through tissue factor expression, which is
expressed at higher levels on AT- and placenta-derived MSCs
(45). Heparin infusion was shown to prevent this effect in a
porcine model of acute myocardial infarction (76). BM-MSCs
have also been used to treat hemorrhages in a few patients
(gastro-intestinal bleeding, hemorrhagic cystitis) (77). The higher
procoagulant effects of UC- and AT-MSCs might be of interest in
these settings.
There are limitations in our study. First, we did not
include placenta-derived decidua stromal cells (DSCs) among
the sources of stromal cells we compared. Indeed, recent studies
in humans have suggested that these cells could be more
potent than BM-MSCs to treat acute GVHD (78). Secondly, it
has been recently demonstrated that monocytes are important
for induction of Tregs by MSCs in vitro (79). Moreover,
in a murine model of GVHD, apoptosis of MSCs induced
by cytolytic cells (NK and CD8+ cells) and phagocytosis of
apoptotic MSCs by macrophages were necessary to MSC-
induced immunosuppression (80). Given that human monocytes
/ macrophages do not engraft in NSG mice, it is possible that
the humanized NSG mouse model is not the most suitable
model to study the impact of MSCs on GVHD. However,
one could argue that NSG mice have nevertheless functional
autologous macrophage and dendritic cells that are able to
modulate the activity of infused human PBMCs (52). Other
potential limitations of this study are the fact that the timing
of the first MSC administration might have been too late, when
irreversible immunological mechanisms were already in place, or
that the GVHD induced by injection of HLA-A2-negative PBMC
in NSG-HLA-A2 mice (combining xeno- and allo- reactions) is
perhaps too strong to be counterbalanced by immune regulatory
mechanisms. However, one could also argue that the dose of
PBMC infused in our study (1–1.5 × 106 PBMC/mice) was
rather in the lower range of what has been used to induce
GVHD in NSG or NSG-HLA-A2 mice. Finally, in order to
take into consideration genetic variability, we elected to include
different PBMC andMSC donors for each experiment to increase
the robustness of our results. In order to tackle the variability
issue, we performed multivariate Cox models that confirmed a
significant impact of the PBMC donors (as previously reported
(36, 37), no impact of mouse gender and weight, as well as no
impact of MSC infusion on survival (Supplementary Table 1).
In summary, our data show that BM-, AT-, and UC-MSCs
have differential effects on immune cells. UC-MSCs seem to
promote a more “resting” phenotype in lymphocytes, with a
potent down-regulation of HLA-DR, a higher induction of Tregs,
and a decreased proportion of pro-inflammatory cells. On the
other hand, BM-MSCs promote higher IL10 expression by T
lymphocytes, but also more inflammatory features, especially
when primed in inflammatory conditions. In vivo, both BM- and
UC-MSCs failed to significantly delay GVHD mortality. Other
types of MSCs derived from fetal membranes seem promising
for GVHD therapy, and it would be interesting to compare
them to BM- and UC-MSCs in preclinical studies. Also, gene
modification of MSCs (for example in order to force secretion
of regulatory cytokines such as IL-10) might increase their ability
to protect against GVHD (81). Finally, the procoagulant effects
of UC-MSCs and AT-MSCs should be taken into consideration
in further clinical studies.
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